Psagot Value Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-5,442
Closed -$208K 485
2023
Q4
$208K Buy
+5,442
New +$50.8K 0.09% 161
2023
Q2
Sell
-300
Closed -$3K 624
2023
Q1
$3K Buy
+300
New +$2.97K ﹤0.01% 389
2022
Q2
Sell
-18,328
Closed -$172K 366
2022
Q1
$172K Buy
+18,328
New +$153K 0.04% 213
2021
Q4
Sell
-14,207
Closed -$138K 448
2021
Q3
$138K Sell
14,207
-522,116
-97% -$4.89M 0.02% 287
2021
Q2
$5.31M Sell
536,323
-4,776,164
-90% -$50.6M 0.19% 82
2021
Q1
$61.3M Buy
5,312,487
+385,583
+8% +$4.42M 1.38% 22
2020
Q4
$47.5M Buy
4,926,904
+440,810
+10% +$4.22M 1.1% 26
2020
Q3
$40.4M Buy
4,486,094
+4,128,139
+1,153% +$43.7M 1.02% 24
2020
Q2
$4.41M Sell
357,955
-912,728
-72% -$10.3M 0.12% 92
2020
Q1
$11.4M Buy
1,270,683
+1,195,498
+1,590% +$12.2M 0.47% 55
2019
Q4
$737K Buy
75,185
+930
+1% +$8.3K 0.02% 196
2019
Q3
$511K Sell
74,255
-34,200
-32% -$262K 0.02% 193
2019
Q2
$1M Sell
108,455
-280
-0.3% -$3.38K 0.04% 169
2019
Q1
$1.71M Buy
108,735
+2,121
+2% +$37.4K 0.07% 145
2018
Q4
$1.64M Sell
106,614
-12,084
-10% -$248K 0.08% 143
2018
Q3
$2.56M Sell
118,698
-14,693
-11% -$341K 0.11% 100
2018
Q2
$3.24M Sell
133,391
-199,616
-60% -$4.07M 0.15% 83
2018
Q1
$5.69M Sell
333,007
-1,193,637
-78% -$23.3M 0.25% 70
2017
Q4
$28.9M Buy
1,526,644
+15,949
+1% +$240K 1.26% 25
2017
Q3
$26.6M Buy
1,510,695
+853,603
+130% +$19.2M 1.12% 26
2017
Q2
$21.8M Buy
657,092
+497,237
+311% +$15.4M 0.94% 31
2017
Q1
$5.13M Buy
159,855
+21,331
+15% +$728K 0.22% 64
2016
Q4
$5.02M Sell
138,524
-110,069
-44% -$4.39M 0.22% 66
2016
Q3
$11.4M Sell
248,593
-821,412
-77% -$42.9M 0.48% 45
2016
Q2
$53.7M Buy
1,070,005
+481,820
+82% +$25.7M 2.32% 12
2016
Q1
$31.5M Buy
588,185
+1,263
+0.2% +$74.1K 1.31% 20
2015
Q4
$38.5M Sell
586,922
-11,063
-2% -$684K 1.38% 17
2015
Q3
$33.8M Buy
597,985
+89,514
+18% +$5.8M 1.22% 19
2015
Q2
$30.1M Buy
+508,471
New +$31.4M 0.95% 23

Other funds holding TEVA

Psagot Value Holdings's TEVA Position: Q1 2024 in Review

Psagot Value Holdings sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 5,442 shares — an estimated $208K sold.

Psagot Value Holdings first reported a position in TEVA in Q2 2015 and held it in 29 quarters. The position peaked at $61.3M in Q1 2021. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Psagot Value Holdings reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Psagot Value Holdings sold 5,442 Teva Pharmaceuticals shares in Q1 2024, an estimated $208K.
  • Psagot Value Holdings first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 29 quarters.
  • Psagot Value Holdings's Teva Pharmaceuticals position peaked at $61.3M in Q1 2021.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Psagot Value Holdings's 13F filing for Q1 2024, filed 15 May 2024.